In T1D, where exogenous insulin is required, protein’s glucagon-stimulating properties can be leveraged to prevent delayed or overnight hypoglycemia, assist during prolonged activity, or enhance mild hypoglycemia treatment (22, 31, 34). Here, INS is linked to type 1 diabetes mellitus.